<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356222</url>
  </required_header>
  <id_info>
    <org_study_id>BH 004</org_study_id>
    <nct_id>NCT04356222</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis</brief_title>
  <official_title>Efficacy and Safety of Durvalumab Combined With Intrathecal Chemotherapy in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui Bu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the clinical efficacy and safety of Durvalumab
      combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal
      metastasis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS was defined as the time between the start of treatment to the date of death or date participant was last known to be alive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Progression Free Survival(NPFS)</measure>
    <time_frame>36 months</time_frame>
    <description>NPFS was defined as the time between the start of treatment until central nervous system metastase progression or death due to any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of adverse reactions</measure>
    <time_frame>36 months</time_frame>
    <description>In accordance with the standard of CTCAE, an assessment will be assessed every 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>NPFS was defined as the time between the start of treatment to the date of the first documented tumor progression as determined by investigators per RECIST 1.1,or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>Investigator assessed ORR was defined as the number of subjects whose best objective response (OOR) was a confirmed complete response (CR) or confirmed partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment</measure>
    <time_frame>36 months</time_frame>
    <description>In accordance with the standard of Response Assessment in Neuro-Oncology(RANO) Neurological Assessment group.The maximum value is 29 and the minimum value is 0.The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <condition>Durvalumab</condition>
  <arm_group>
    <arm_group_label>Leptomeningeal Metastasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + Intrathecal chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Intravenous infusion once every two weeks ,once 10mg/kg.</description>
    <arm_group_label>Leptomeningeal Metastasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Intrathecal chemotherapy specified dose on specified days</description>
    <arm_group_label>Leptomeningeal Metastasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female age 18 or more

          2. Pathologically proven non-small cell lung cancer

          3. MRI(Magnetic Resonance Imaging,MRI) imaging findings or the detection of malignant
             cells in cerebrospinal fluid

          4. Patients have the ability to understand and the willingness to sign a written informed
             consent document.

        Exclusion Criteria:

          1. KPS score &lt;60

          2. History of autoimmune diseases

          3. With severe hepatic and renal dysfunction

          4. Has a history of (non-infectious) pneumonitis that required steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Bu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Bu</last_name>
    <phone>86-13831106903</phone>
    <email>buhuimy1@163.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Hui Bu</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Leptomeningeal Metastasis</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Intrathecal chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

